All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Many different strategies are being investigated to develop "off-the-shelf" CAR T-cell therapies. The cumbersome manufacturing process and high cost of autologous CAR T cells may prevent some patients from receiving the treatment. Using induced pluripotent stem cells (iPSCs) as a starting source for CAR T cells is an attractive approach.
Our CAR-iT cells are engineered by incorporating a second-generation CAR into iPSCs-derived T cells using lentiviral transduction technology. These CAR-iT cells are expected to lysis tumor cells in vitro and demonstrated anti-tumor function in vivo.
There are currently no customer reviews or questions for Anti-ULBP1 (XP5-301) h(CD28-CD3ζ) CAR-iT Cells (XS-0622-ZP301). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION